Evaluation of the effectiveness of Empagliflozin on metabolic factors and liver function tests
Phase 3
Recruiting
- Conditions
- Type 2 diabetes mellitus.Diabetes mellitus due to underlying condition
- Registration Number
- IRCT20191209045671N3
- Lead Sponsor
- Semnan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
All type 2 diabetic patients with non-alcoholic fatty liver
Having the consent to participate in the study
Age between 20 to 65 years
Healthy physical status
Exclusion Criteria
history of taking SGLT2 inhibitors
being pregnant for women
history of malignancy and diseases such as AIDS and hepatitis
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum SGPT level. Timepoint: Before and after the study. Method of measurement: Biochemical-laboratory methods.;Serum SGOT level. Timepoint: Before and after the intervention. Method of measurement: Biochemical-laboratory methods.;Blood glucose level. Timepoint: Before and after the intervention. Method of measurement: Biochemical-laboratory methods.;Serum ALK level. Timepoint: Before and after the intervention. Method of measurement: Biochemical-laboratory methods.
- Secondary Outcome Measures
Name Time Method